|Bid||26.50 x 0|
|Ask||26.90 x 0|
|Day's range||26.36 - 28.40|
|52-week range||22.02 - 109.10|
|Beta (5Y monthly)||0.63|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Investors need to pay close attention to Orphazyme (ORPH) stock based on the movements in the options market lately.
Shares of Orphazyme (NASDAQ: ORPH) skyrocketed 24.6% as of the market close on Wednesday after rising as much as 56.6% earlier in the day. The big gain came after the drugmaker announced that Goldman Sachs (NYSE: GS) temporarily increased its stake to 5.58% on Jun. 16, 2021, but then reduced its position to less than 5% the following day. What does the "major shareholder announcement" made by Orphazyme today mean for investors?
A lot of everyday investors recently lost a bundle betting that the Food and Drug Administration would approve an experimental drug from Orphazyme (NASDAQ: ORPH). There were reasons to suspect arimoclomol might earn approval to treat a rare life-threatening disease. There were also plenty of reasons to keep your portfolio far away from Orphazyme's attempt to earn approval for its first drug.